Department of Medicine, Division of Hospital Medicine, University of Colorado, Aurora, CO, USA; Department of Medicine, Division of General Internal Medicine, University of Colorado, Aurora, CO, USA.
Department of Medicine, Division of General Internal Medicine, University of Colorado, Aurora, CO, USA.
Drug Alcohol Depend. 2024 Sep 1;262:111409. doi: 10.1016/j.drugalcdep.2024.111409. Epub 2024 Jul 28.
In the U.S., overdose deaths and substance treatment admissions related to methamphetamine are rising. This study aims to measure and compare U.S. temporal trends in methamphetamine-involved psychiatric hospitalizations.
We conducted a population-based, trend analysis of U.S. psychiatric hospitalizations and calculated quarterly (Q) rates per 100,000 population of substance-involved psychiatric hospitalizations. We assessed U.S. regional quarterly percentage hospitalization rate changes using Joinpoint regression.
From Q4 2015-Q4 2019, there were 963,202 psychiatric hospitalizations, 50,223 (5.2 %) involved methamphetamine and 102,877 (10.7 %) involved opioids and/or cocaine without methamphetamine. Methamphetamine-involved psychiatric hospitalization rates increased by 68.0 %, psychiatric hospitalizations rates involving opioid and/or cocaine without methamphetamine decreased by 22 %, while nonsubstance-involved psychiatric hospitalizations rates remained unchanged. The largest significant increases in methamphetamine-involved psychiatric hospitalization rates were among people >61 years old, males, and Midwesterners. Methamphetamine-involved psychiatric hospitalization rates doubled among Black patients. The largest average percent increase among methamphetamine-involved psychiatric hospitalizations was 10.2 % from Q4 2015-Q2 2017 in the Midwest.
Most psychiatric hospitalizations did not involve substances. Methamphetamine-involved psychiatric hospitalizations greatly increased while opioid-involved psychiatric hospitalizations decreased, but involved more total encounters. Greater access to harm reduction services, contingency management programs, and mental health services is urgently needed.
在美国，与冰毒相关的药物过量死亡和药物治疗入院人数正在上升。本研究旨在衡量和比较美国与冰毒相关的精神科住院治疗的时间趋势。
我们进行了一项基于人群的、美国精神科住院治疗的趋势分析，并计算了每 10 万人中有多少人因物质使用而住院的季度（Q）率。我们使用 Joinpoint 回归评估了美国地区每季度住院率变化的百分比。
从 2015 年第四季度到 2019 年第四季度，共有 963202 例精神科住院治疗，其中 50223 例（5.2%）涉及冰毒，102877 例（10.7%）涉及阿片类药物和/或可卡因而没有冰毒。涉及冰毒的精神科住院治疗率增加了 68.0%，涉及阿片类药物和/或可卡因而没有冰毒的精神科住院治疗率下降了 22%，而没有涉及物质的精神科住院治疗率保持不变。涉及冰毒的精神科住院治疗率增长最大的是年龄在 61 岁以上的人群、男性和中西部地区的人群。黑人患者中涉及冰毒的精神科住院治疗率翻了一番。在涉及冰毒的精神科住院治疗中，增长率最大的是在 2015 年第四季度至 2017 年第二季度期间，中西部地区的增长率为 10.2%。
大多数精神科住院治疗并不涉及物质。涉及冰毒的精神科住院治疗大大增加，而涉及阿片类药物的精神科住院治疗减少，但涉及的总人次更多。迫切需要更多的减少伤害服务、强制性管理计划和心理健康服务。
